H. Lundbeck A/S increases its share capital by 139,333 shares (0.0707% of outstanding shares) as a result of employee warrant exercise
Valby, Denmark, 17 November 2015 - H. Lundbeck A/S (Lundbeck) today announced that it has decided to increase its share capital by DKK 696,665, as a consequence of the exercise of employee warrants.
The increase is affected without any preemption rights for the existing shareholders of the company or others. The shares are subscribed in cash at the following prices per share of nominally DKK 5: 11,701 shares at DKK 115, 14,730 shares at DKK 102, 20,676 shares at DKK 97, 44,358 shares at DKK 121 and 47,868 shares at DKK 113. Proceeds to the company are DKK 15,630,049 (approximately USD 2,246,481). The increase corresponds to approximately 0.0707% of the company's share capital.
The new shares are ordinary shares without any special rights and are freely transferable negotiable instruments. The new shares shall give rights to dividends and other rights in relation to the company from the time of registration of the capital increase, i.e. inter alia full rights to dividends for the financial year 2015. The new shares will be listed on NASDAQ OMX Copenhagen after registration with the Danish Business Authority. Lundbeck's current share capital amounts to DKK 985,809,740 and will after the capital increase be DKK 986,506,405. The capital increase is expected to be finalized shortly.
|Palle Holm Olesen||Mads Kronborg|
|Vice President, Investor Relations||Director, Media Relations|
|+45 36 43 24 26||+45 36 43 30 00|
Lundbeck (LUN.CO, LUN DC, HLUYY) is a global pharmaceutical company specialized in brain diseases. For more than 70 years, we have been at the forefront of research within neuroscience. Our key areas of focus are Alzheimer’s disease, depression, Parkinson’s disease and psychosis.
An estimated 700 million people worldwide are living with brain disease and far too many suffer due to inadequate treatment, discrimination, a reduced number of working days, early retirement and other unnecessary consequences. Every day, we strive for improved treatment and a better life for people living with brain disease – we call this Progress in Mind.
Our approximately 5,500 employees in 57 countries are engaged in the entire value chain throughout research, development, production, marketing and sales. Our pipeline consists of several late-stage development programmes and our products are available in more than 100 countries. We have research centres in China and Denmark and production facilities in China, Denmark, France and Italy. Lundbeck generated core revenue of DKK 13.5 billion in 2014 (EUR 1.8 billion; USD 2.4 billion).
For additional information, we encourage you to visit our corporate site www.lundbeck.com and connect with us on Twitter at @Lundbeck.